Jonathan Gardner
Senior Reporter | @ByJonGardner
863 articles by Jonathan Gardner
-
Drug patents protect pharma profits. Track when they’ll expire here.
May 8, 2024 -
AstraZeneca ups stake in Cellectis in latest cell therapy bet
May 6, 2024 -
Amgen shares soar as executives outline obesity drug push
May 3, 2024 -
Novo sees Wegovy sales dip on lower price, tight supply
May 2, 2024 -
Lilly counts on manufacturing scale-up to unstick obesity drug supply
April 30, 2024 -
Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound
April 30, 2024 -
AbbVie tries to reassure investors on Humira biosimilar threat
April 26, 2024 -
AstraZeneca’s earnings surprise investors as cancer drugs fuel growth
April 25, 2024 -
Eisai hunts for next Alzheimer’s drug with new research pact
April 22, 2024 -
Alvotech deal could heighten biosimilar pressure on Humira
April 19, 2024 -
Lilly obesity drug shows benefit in sleep disorder study, pointing to new use
April 17, 2024 -
Roche reports survival data for new dual-acting lymphoma drug
April 15, 2024 -
European regulator concludes no suicide link to obesity drugs
April 12, 2024 -
Novartis pauses enrollment in some Kisqali trials to fix manufacturing
April 10, 2024 -
Trial shows Wegovy can ease heart failure symptoms
April 8, 2024 -
Bristol Myers says KRAS drug succeeds in key trial
March 29, 2024 -
FDA approves Akebia anemia pill, two years after rejection
March 28, 2024 -
FDA approves Merck lung disease drug acquired in $11B deal
March 26, 2024 -
Viking stays in obesity drug race with early data for weight loss pill
March 26, 2024 -
FDA rejects Regeneron lymphoma drug, setting back company’s oncology push
March 25, 2024 -
Roche autoimmune disease drug disappoints in closely watched trial
March 21, 2024 -
FDA panel backs broader use of J&J, Bristol Myers cell therapies for myeloma
March 15, 2024 -
BIO changes stance, backs bill to limit China’s role in US biotech
March 14, 2024 -
FDA to focus on ‘early deaths’ in meeting on broader CAR-T use in myeloma
March 13, 2024 -
Roche, following setbacks, turns to its next Alzheimer’s drug
March 11, 2024